Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lionel Schachna

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Australian Family Physician|November 13, 2013
Ankylosing spondylitis: an updateVera Golder, Lionel Schachna
Current Opinion in Rheumatology|November 1, 2002
Targeting mediators of vascular injury in sclerodermaLionel Schachna, Fredrick M Wigley
Arthritis Care & Research|December 17, 2013
Understanding presenteeism in patients with ankylosing spondylitis: contributing factors and association with sick leaveVladimir S Gordeev, Walter P Maksymowych, Lionel Schachna, et al.
The Journal of Rheumatology|February 9, 2006
Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in sclerodermaBetty Chang, Lionel Schachna, Barbara White, et al.
Clinical Rheumatology|February 2, 2010
Tumour necrosis factor inhibitor-related lupus: safety of switching agentsJessica M T Luong, Boon T Tan, Russell R C Buchanan, et al.
Arthritis and Rheumatism|July 19, 2002
Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital lossLionel Schachna, Fredrick M Wigley, Steven Morris, et al.
Chest|December 11, 2003
Age and risk of pulmonary arterial hypertension in sclerodermaLionel Schachna, Fredrick M Wigley, Betty Chang, et al.
Clinical Rheumatology|February 17, 2009
What factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis?Dessy W Fajri, Caroline A Brand, Shyamali C Dharmage, et al.
International Journal of Rheumatology|January 29, 2010
Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association databaseJohn Oldroyd, Lionel Schachna, Rachelle Buchbinder, et al.
Clinical Rheumatology|November 6, 2008
Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional studySimon M Chatfield, Shyamali C Dharmage, Anthony Boers, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Australian Family Physician|November 13, 2013
Ankylosing spondylitis: an updateVera Golder, Lionel Schachna
Current Opinion in Rheumatology|November 1, 2002
Targeting mediators of vascular injury in sclerodermaLionel Schachna, Fredrick M Wigley
Arthritis Care & Research|December 17, 2013
Understanding presenteeism in patients with ankylosing spondylitis: contributing factors and association with sick leaveVladimir S Gordeev, Walter P Maksymowych, Lionel Schachna, et al.
The Journal of Rheumatology|February 9, 2006
Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in sclerodermaBetty Chang, Lionel Schachna, Barbara White, et al.
Clinical Rheumatology|February 2, 2010
Tumour necrosis factor inhibitor-related lupus: safety of switching agentsJessica M T Luong, Boon T Tan, Russell R C Buchanan, et al.
Arthritis and Rheumatism|July 19, 2002
Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital lossLionel Schachna, Fredrick M Wigley, Steven Morris, et al.
Chest|December 11, 2003
Age and risk of pulmonary arterial hypertension in sclerodermaLionel Schachna, Fredrick M Wigley, Betty Chang, et al.
Clinical Rheumatology|February 17, 2009
What factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis?Dessy W Fajri, Caroline A Brand, Shyamali C Dharmage, et al.
International Journal of Rheumatology|January 29, 2010
Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association databaseJohn Oldroyd, Lionel Schachna, Rachelle Buchbinder, et al.
Clinical Rheumatology|November 6, 2008
Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional studySimon M Chatfield, Shyamali C Dharmage, Anthony Boers, et al.
Pageof 2